# US 2004/0081973 A1 · Cloning and characterization of a novel BK channel isoform highly expressed in glioma cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081973 A1
- Document ID: US20040081973A1
- Status: Published application
- Kind: A1
- Application number: 10/375,293
- Filed: 2003-02-27
- Published: 2004-04-29
- Earliest claimed: 2002-02-28
- Inventors: Harald W. Sontheimer; Xiaojin Liu
- Web page: https://patentgrep.com/patent/US20040081973A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described is the cloning and functional characterization of a novel splice variant of hSlo, the gene encoding the α-subunit of IbTX sensitive human BK channels. The novel isoform of BK channels, which was termed gBK, contains a 63 amino acid insert at splice site 2, which differs by 33 amino acids from its nearest relative hbr5. gBK channels were over-expressed in glioma cells as evident from examination of human biopsy specimens. Moreover, gBK channel expression correlated positively with the relative degrees of malignancy of the tumor tissues. Heterologous expression of gBK in oocytes revealed that the pharmacological and biophysical properties of gBK are consistent with the properties of native BK currents in glioma cells. Furthermore, even when compared with its most homologous form hbr5, gBK showed distinct properties, including slowed channel activation and importantly, enhanced Ca2+ sensitivity at physiologically relevant [Ca2+]i values.

## Claims

### Claim 1

An isolated and purified nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 12, or a functional derivative of SEQ ID. NO: 12.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 where said sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 14.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1 where said sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 14, or a fragment of SEQ ID NO: 14 at least 5 residues in length.

### Claim 4

An isolated and purified nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 13, or a functional derivative of SEQ ID. NO: 13.

### Claim 5 (depends on 4)

The nucleic acid molecule of claim 4 where said sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 15.

### Claim 6 (depends on 4)

The nucleic acid molecule of claim 4 where said sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 15, or a fragment of SEQ ID NO: 15 at least 5 residues in length.

### Claim 7 (depends on 4)

The nucleic acid molecule of claim 4 comprising a sequence of which is at least 50% identical to SEQ ID NO: 13

### Claim 8

An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe the nucleotide sequence of which consists of the sequences selected from the group consisting of SEQ ID NO: 12, the complement of SEQ ID NO: 12, a fragment of SEQ ID NO: 12 at least 15 nucleotides in length, the complement of a fragment of SEQ ID NO: 12 at least 15 nucleotides in length SEQ ID NO: 13, the complement of SEQ ID NO: 13, a fragment of SEQ ID NO: 13 at least 15 nucleotides in length and the complement of a fragment of SEQ ID NO: 13 at least 15 nucleotides in length.

### Claim 9

A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 14, or a degenerate variant of SEQ ID NO: 14.

### Claim 10 (depends on 9)

The polypeptide of claim 9 where the V0.5 value at an intracellular calcium concentration of 0 M is +144 mV when said polypeptide is expressed in STTG-1 cells.

### Claim 11 (depends on 9)

The purified polypeptide of claim 9 where said amino acid sequence comprises at least 5 consecutive amino acids of SEQ ID NO: 14.

### Claim 12

A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 15, or a degenerate variant of SEQ ID NO: 15.

### Claim 13 (depends on 12)

The purified polypeptide of claim 12 where said amino acid sequence comprises at least 5 consecutive amino acids of SEQ ID NO: 15.

### Claim 14 (depends on 12)

The purified polypeptide of claim 12 where said amino acid sequence is at least 50% identical to SEQ ID NO: 15.

### Claim 15 (depends on 12)

The purified polypeptide of claim 12 further comprising phosphorylation sites for at least one protein kinase.

### Claim 16 (depends on 15)

The purified protein of claim 15 where the at least one protein kinase is selected from the group consisting of casein kinase I, protein kinase C and multi functional calmodulin-dependent kinase.

### Claim 17 (depends on 3)

An expression vector comprising the nucleic acid of claim 3 operably linked to an expression control sequence.

### Claim 18 (depends on 3)

A non-human cell comprising the nucleic acid of claim 3 operably linked to an expression control sequence.

### Claim 19 (depends on 18)

The cell of claim 18 further comprising a modulating compound.

### Claim 20 (depends on 19)

The cell of claim 19 where the modulating compound is a β-subunit of a BK channel.

### Claim 21 (depends on 18)

A method of producing a polypeptide, the method comprising culturing the cells of claim 18 under conditions permitting expression of the polypeptide.

### Claim 22 (depends on 21)

The method of claim 21 further comprising purifying the polypeptide from the cell of the medium of the cell.
